BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Menaquinone

...activity in topical applications (See Cover Story). TARGET/MARKER/PATHWAY: Menaquinone LICENSING STATUS: Patent issued; licensed to Genome Pharmaceuticals...
BioCentury | Jan 22, 2015
Targets & Mechanisms

Unearthing antibiotics

With antibiotic discovery coming back into vogue, two groups have literally gone to ground to find new compounds produced by bacteria in the soil. Using designed-for-purpose screening systems, the teams identified two unknown antimicrobial peptides...
BioCentury | May 20, 2013
Company News

Evotec, Harvard deal

...declined to disclose details. Evotec previously partnered on antibiotics deals with GPC Biotech AG (formerly Genome Pharmaceuticals Corp. AG...
BioCentury | Apr 12, 1999
Company News

Evotec BioSystems, Genome Pharmaceuticals deal

...broad-spectrum antibiotics based on genomics-derived targets. Genome Pharmaceuticals will provide Evotec with antibacterial targets identified using Genome Pharmaceuticals’...
...at which point they will seek a pharmaceutical partner. Evotec Biosystems AG , Hamburg, Germany Genome Pharmaceuticals Corp. AG...
BioCentury | Apr 5, 1999
Company News

Genome Pharmaceuticals, Gene Alliance deal

...pharmaceutical, agricultural and food companies. The program will initially focus on pharmacogenomics and agricultural biotech. Genome Pharmaceuticals...
...and Qiagen GmbH (Hilden, Germany), a subsidiary of Qiagen N.V. (NMarkt:QIA; QGENF, Venlo, the Netherlands). Genome Pharmaceuticals Corp. AG...
BioCentury | Mar 15, 1999
Company News

Cytovia board of directors update

...Cytovia Inc., San Diego, Calif. Business: Cancer, Autoimmune/Inflammation, Neurological Appointed: Bernd Seizinger, CEO of Genome Pharmaceuticals Corp. WIR...
BioCentury | Feb 1, 1999
Company News

Genome Pharmaceuticals scientific advisory board update

Genome Pharmaceuticals Corp. AG, Munich, Germany Business: Drug discovery, Infectious diseases, Autoimmune/Inflammation Appointed: Jurgen Drews, chairman of the European Association for Bioindustries (EuropaBio), as chairman, and also named chief strategic officer, while remaining on the...
BioCentury | Dec 7, 1998
Company News

Genome Pharmaceuticals, Altana AG deal

...collaborate on new genomic targets to control infections caused by Helicobacter pylori and Chlamydia pneumoniae. Genome Pharmaceuticals...
...develop drugs and diagnostics. The deal is worth up to DM50 million (US$30 million) to Genome Pharmaceuticals...
...milestones. In the first stage of the five-year alliance, three projects will be funded at Genome Pharmaceuticals...
BioCentury | Oct 12, 1998
Company News

Genome Pharmaceuticals Corp. AG. management update

Genome Pharmaceuticals Corp. AG., Munich, Germany Business: Drug discovery Hired: Bernd Seizinger as CEO, formerly EVP and CSO at Genome Therapeutics Inc.; he replaces acting CEO Michael Steinmetz, managing director of MPM Asset Management, who...
BioCentury | Sep 28, 1998
Company News

Genome Pharmaceuticals Corp. GmbH other research news

...targets expressed during the activation of T helper (Th) cells using the company's genomics technology. Genome Pharmaceuticals...
Items per page:
1 - 10 of 15
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Menaquinone

...activity in topical applications (See Cover Story). TARGET/MARKER/PATHWAY: Menaquinone LICENSING STATUS: Patent issued; licensed to Genome Pharmaceuticals...
BioCentury | Jan 22, 2015
Targets & Mechanisms

Unearthing antibiotics

With antibiotic discovery coming back into vogue, two groups have literally gone to ground to find new compounds produced by bacteria in the soil. Using designed-for-purpose screening systems, the teams identified two unknown antimicrobial peptides...
BioCentury | May 20, 2013
Company News

Evotec, Harvard deal

...declined to disclose details. Evotec previously partnered on antibiotics deals with GPC Biotech AG (formerly Genome Pharmaceuticals Corp. AG...
BioCentury | Apr 12, 1999
Company News

Evotec BioSystems, Genome Pharmaceuticals deal

...broad-spectrum antibiotics based on genomics-derived targets. Genome Pharmaceuticals will provide Evotec with antibacterial targets identified using Genome Pharmaceuticals’...
...at which point they will seek a pharmaceutical partner. Evotec Biosystems AG , Hamburg, Germany Genome Pharmaceuticals Corp. AG...
BioCentury | Apr 5, 1999
Company News

Genome Pharmaceuticals, Gene Alliance deal

...pharmaceutical, agricultural and food companies. The program will initially focus on pharmacogenomics and agricultural biotech. Genome Pharmaceuticals...
...and Qiagen GmbH (Hilden, Germany), a subsidiary of Qiagen N.V. (NMarkt:QIA; QGENF, Venlo, the Netherlands). Genome Pharmaceuticals Corp. AG...
BioCentury | Mar 15, 1999
Company News

Cytovia board of directors update

...Cytovia Inc., San Diego, Calif. Business: Cancer, Autoimmune/Inflammation, Neurological Appointed: Bernd Seizinger, CEO of Genome Pharmaceuticals Corp. WIR...
BioCentury | Feb 1, 1999
Company News

Genome Pharmaceuticals scientific advisory board update

Genome Pharmaceuticals Corp. AG, Munich, Germany Business: Drug discovery, Infectious diseases, Autoimmune/Inflammation Appointed: Jurgen Drews, chairman of the European Association for Bioindustries (EuropaBio), as chairman, and also named chief strategic officer, while remaining on the...
BioCentury | Dec 7, 1998
Company News

Genome Pharmaceuticals, Altana AG deal

...collaborate on new genomic targets to control infections caused by Helicobacter pylori and Chlamydia pneumoniae. Genome Pharmaceuticals...
...develop drugs and diagnostics. The deal is worth up to DM50 million (US$30 million) to Genome Pharmaceuticals...
...milestones. In the first stage of the five-year alliance, three projects will be funded at Genome Pharmaceuticals...
BioCentury | Oct 12, 1998
Company News

Genome Pharmaceuticals Corp. AG. management update

Genome Pharmaceuticals Corp. AG., Munich, Germany Business: Drug discovery Hired: Bernd Seizinger as CEO, formerly EVP and CSO at Genome Therapeutics Inc.; he replaces acting CEO Michael Steinmetz, managing director of MPM Asset Management, who...
BioCentury | Sep 28, 1998
Company News

Genome Pharmaceuticals Corp. GmbH other research news

...targets expressed during the activation of T helper (Th) cells using the company's genomics technology. Genome Pharmaceuticals...
Items per page:
1 - 10 of 15